There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...

Advisor engaged in evaluating strategic options to maximize shareholder valueCash balance of $76.6 million as of December 31, 2024UTRECHT, The ...